Physician’s Profile

Selim M. Arcasoy, MD, MPH

1
Top Doctor: 
1
Medical Program Director, Lung Transplant Program
Expertise: 
Chronic Lung Disease
Chronic Obstruct Pulm Disease/COPD
Critical Care Medicine
Emphysema
General Pulmonology
Hypersensitivity Pneumonitis
Idiopathic Pulmonary Fibrosis
Internal Medicine
Lung Transplant
Pediatric Pulmonology
Pulmonary Critical Care Medicine
Pulmonary Disease
Pulmonary Fibrosis
Pulmonary Medicine
Pulmonology
Respiratory Failure
Restrictive Lung Diseases
Transplant Pulmonology
About: 

Dr. Arcasoy was recruited to Columbia University as the Medical Program Director of Lung Transplantation in 2001 from the University of Pennsylvania. After his recruitment, he completely turned around the Lung Transplantation Program to rank amongst the top 5 to 10 programs in the country with regard to volume and patient survival.  Under his leadership, the Lung Transplant Program has been performing more than 80 transplants annually.  In October 2019, Dr. Arcasoy and his team celebrated their 1000th lung transplant since 2001.  Despite high transplant volumes and very sick pretransplant candidates, the survival of lung transplant recipients has remained stellar.  Currently, 1-year survival of lung transplant recipients at Columbia University is 90%, 5-year survival 65%, and 10-year survival 42%. 

Dr. Arcasoy has gained national and international reputation with various leadership roles in professional organizations and scientific societies.  He previously chaired the Thoracic Organ Transplant Committee of the AST and the Transplant Network Steering Committee of the ACCP.  He recently served in the Thoracic Organ Transplant Committee of the OPTN to develop Continuous Distribution of Lungs. He is currently the Associate Chair for Advanced Lung Failure and Transplantation in the Standards and Guidelines Committee of the ISHLT.

Honors: 

2016: Fellow of the American Society of Transplantation (F.A.S.T.)

2002-21: Inclusion in America’s Top Doctors and Top Doctors: New York Metro Area

2009-21: Inclusion in New York City Super Doctors, New York Times Magazine

2002: Fellow of the American College of Physicians (F.A.C.P.)

2001: Fellow of the American College of Chest Physicians (F.C.C.P.)

1999: Rank Valedictorian of class in Ege University School of Medicine

1984: Rank Valedictorian of class in Tarsus American College

Interests: 
Co-morbidities in advanced pulmonary disease
Collaborative investigation in immune tolerance
Idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis
Lung volume reduction for emphysema
Novel immunosuppressive regimens and antimicrobial therapies in lung transplantation
Outcomes of patients with advanced lung disease before and after transplantation
Patient selection and outcomes on the waiting list for lung transplantation
Post-transplant complications
Predictors and diagnosis of acute and chronic lung rejection
Pulmonary embolism and thrombolytic therapy
Studies of genetic testing for diagnosis of organ rejection
Publications: 
A.M. Layton, H.F. Armstrong, H.P. Kim, K.S. Meza, F. D’Ovidio, S.M. Arcasoy. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med 2017; 126: 59-67.
J.M. Diamond, S. Arcasoy, C.C. Kennedy, M. Eberlein, J.P. Singer, G.M. Patterson, J.D. Edelman, G. Dhillon, T. Pena, S.M. Kawut, J.C. Lee, R. Girgis, J. Dark, G. Thabut. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017 Oct;36(10):1104-1113.
L.J. Benvenuto, D.R. Anderson, H.P. Kim, J.L. Hook, L. Shah, H.Y. Robbins, F. D’Ovidio, M. Bacchetta, J.R. Sonett, S.M. Arcasoy. Geographic disparities in donor lung supply and lung transplant waitlist outcomes: A Cohort Study. Am J Transplant; 2018; 18:1471-80
L.J. Benvenuto, M.R. Anderson, S.M. Arcasoy.  New frontiers in immunosuppression. J Thorac Dis 2018;10(5):3141-55. 
M. Aversa, L. Benvenuto, H. Kim, L. Shah, H. Robbins, B.P. Stanifer, F. D'Ovidio, E.R. Vasilescu, J. Sonett, S.M. Arcasoy. Effect of Calculated Panel Reactive Antibody Value on Waitlist Outcomes for Lung Transplant Candidates. Ann Transplant 2019 Jun 28;24:383-392. 
D. Rudym, L. Benvenuto, J. Costa, M. Aversa, H. Robbins, L. Shah, H. Kim, B.P. Stanifer, J. Sonett, F. D’Ovidio, S.M. Arcasoy. What Awaits on the Other Side: Post-Lung Transplant Morbidity and Mortality After Pre-Transplant Hospitalization. Ann Transplant 2020;25:e922641. 
M. Aversa, L. Benvenuto, M. Anderson, L. Shah, H. Robbins, M. Pereira, J. Scheffert, M. Carroll, J. Hum, M. Nolan, G. Reilly, P. Lemaitre, B.P. Stanifer, F. D’Ovidio, J. Sonett, S. Arcasoy. Covid-19 in lung transplant recipients: A single center case series from New York City. Am J Transplant 2020; 20:3072-80.